Author:
Russo Andrea,Castiglione Fabio,Salonia Andrea,Benigni Fabio,Rigatti Patrizio,Montorsi Francesco,Andersson Karl-Erik,Hedlund Petter
Reference30 articles.
1. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia;Comaru-Schally;J Clin Endocrinol Metab,1998
2. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia;Debruyne;Eur Urol,2008
3. LHRH antagonist cetrorelix for symptomatic BPH: prolonged improvement beyond end of treatment in placebo-controlled trials;Debruyne;Eur Urol Suppl,2008
4. The efficacy and safety of ozarelix, a novel GNRH antagonist, in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH);Debruyne;J Urol,2007
5. Aeterna Zentaris announces results from two phase 3 studies with cetrorelix in benign prostatic hyperplasia. FierceBiotech Web site. http://www.fiercebiotech.com/press-releases/aeterna-zentaris-announces-results-two-phase-3-studies-cetrorelix-benign-prostatic--0. Updated August 17, 2009.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献